Mucosal CD8+ T cell responses induced by an MCMV based vaccine vector confer protection against influenza challenge.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Oduro, Jennifer D
Boehme, Julia D
Pils, Marina C
Guzmán, Carlos A
MetadataShow full item record
AbstractCytomegalovirus (CMV) is a ubiquitous β-herpesvirus that establishes life-long latent infection in a high percentage of the population worldwide. CMV induces the strongest and most durable CD8+ T cell response known in human clinical medicine. Due to its unique properties, the virus represents a promising candidate vaccine vector for the induction of persistent cellular immunity. To take advantage of this, we constructed a recombinant murine CMV (MCMV) expressing an MHC-I restricted epitope from influenza A virus (IAV) H1N1 within the immediate early 2 (ie2) gene. Only mice that were immunized intranasally (i.n.) were capable of controlling IAV infection, despite the greater potency of the intraperitoneally (i.p.) vaccination in inducing a systemic IAV-specific CD8+ T cell response. The protective capacity of the i.n. immunization was associated with its ability to induce IAV-specific tissue-resident memory CD8+ T (CD8TRM) cells in the lungs. Our data demonstrate that the protective effect exerted by the i.n. immunization was critically mediated by antigen-specific CD8+ T cells. CD8TRM cells promoted the induction of IFNγ and chemokines that facilitate the recruitment of antigen-specific CD8+ T cells to the lungs. Overall, our results showed that locally applied MCMV vectors could induce mucosal immunity at sites of entry, providing superior immune protection against respiratory infections.
CitationPLoS Pathog. 2019 Sep 16;15(9):e1008036. doi: 10.1371/journal.ppat.1008036. eCollection 2019 Sep.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Immunization with a murine cytomegalovirus based vector encoding retrovirus envelope confers strong protection from Friend retrovirus challenge infection.
- Authors: Bongard N, Le-Trilling VTK, Malyshkina A, Rückborn M, Wohlgemuth K, Wensing I, Windmann S, Dittmer U, Trilling M, Bayer W
- Issue date: 2019 Sep
- The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus.
- Authors: Tan AC, Deliyannis G, Bharadwaj M, Brown LE, Zeng W, Jackson DC
- Issue date: 2013 Jan
- Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice.
- Authors: Wang J, Shu T, Deng W, Zheng Y, Liao M, Ye X, Han L, He P, Zheng X, Li T, Feng Y, Hu F, Li P, Sun C, Chen L, Li F, Feng L
- Issue date: 2021 May 24
- CCR2 Regulates Vaccine-Induced Mucosal T-Cell Memory to Influenza A Virus.
- Authors: Lee W, Kingstad-Bakke B, Kedl RM, Kawaoka Y, Suresh M
- Issue date: 2021 Jul 12
- Conserved T-cell epitopes of respiratory syncytial virus (RSV) delivered by recombinant live attenuated influenza vaccine viruses efficiently induce RSV-specific lung-localized memory T cells and augment influenza-specific resident memory T-cell responses.
- Authors: Matyushenko V, Kotomina T, Kudryavtsev I, Mezhenskaya D, Prokopenko P, Matushkina A, Sivak K, Muzhikyan A, Rudenko L, Isakova-Sivak I
- Issue date: 2020 Oct